Increasing somatostatin analogues until effective [multiple letters]

Gynecologic Oncology

Volumn 96, Issue 3, 2005, Pages 906-907

  Geisler, John P ^a   Manahan, Kelly J ^b   Menczer, Joseph ^c   Wilder, James ^d  

^a Indiana Women's Oncology PC   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c WOLFSON MEDICAL CENTER   (Israel)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

CYTOREDUCTIVE SURGERY; DISEASE DURATION; DRUG DOSE REGIMEN; ENTEROCUTANEOUS FISTULA; HUMAN; HYPERGLYCEMIA; LETTER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 13844275998     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.12.004     Document Type: Letter

References (1)

1. J.L. Wilder E. Pavlik J.M. Straughn Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation Gynecol. Oncol. 89 2003 233 235